Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. - Wikidata - awgldk - TriplyDB

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

http://www.wikidata.org/entity/Q35071430

about

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Novel immunotherapies in lymphoid malignancies Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1 Adoptive T-cell therapy for cancer: The era of engineered T cells CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma CAR T Cell Therapy: A Game Changer in Cancer Treatment T-cell receptor gene therapy--ready to go viral?Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.Seatbelts in CAR therapy: How Safe Are CARS?Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies.Fully human CD19-specific chimeric antigen receptors for T-cell therapy.From rabbit antibody repertoires to rabbit monoclonal antibodies Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K/Akt pathway.Engineered T cells: the promise and challenges of cancer immunotherapy.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.Molecular genetics and targeted therapy of WNT-related human diseases (Review).An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors.Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia.Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.Treating hematological malignancies with cell therapy: where are we now?T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology.Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.

P2860

Q26769884-A0E1DCC4-E45C-442F-8D76-9F0A59F3822C Q26777394-32338578-CD4C-40B1-AB90-6FAF35FE7EC0 Q26795679-37AF4517-1C76-4222-983D-FD4D35478BB2 Q26800611-0CD22F52-6365-4315-89C2-A356336FC7E7 Q26800814-1CEC5902-303A-4B0F-A7D6-BCD5FCEB9B72 Q26822769-5A287FAB-BEB3-441A-85A0-B817A25D1C0C Q28081611-0E059AA4-AE9F-426E-8EC4-F284BA929818 Q33833475-44993CA0-A958-404C-B39F-14CDF4581FE0 Q35648352-73B8C544-42EA-4467-B875-69398FE2E46A Q35690979-752A18FD-1ACD-4FA1-A0B7-0F4B46612A7E Q35818365-C4386EEC-D3BD-4BB4-AD4D-9E48CBB54E15 Q36015721-CA19BEA8-7D31-4E78-AB69-32ACDAC0DEC2 Q36281920-F5F80B0D-3840-4749-81EF-9AA52DD3DAA2 Q37739483-6F8F3BE6-1D7C-4C08-B466-5B80F7472FD2 Q38429183-46383B65-7FC0-4F33-9E13-B7656361B9B9 Q38775177-BB5CE938-D6CD-4F77-9FE2-45CE9337FD13 Q38824230-9732B41E-A86C-4A57-8BCA-A5B0DF830249 Q38828829-1E0DD0BD-9F3B-46CD-A972-6F02F732A1B0 Q38913549-7A6BBB16-61A5-4667-B76E-3FE05090B5D9 Q39182547-07185CDD-110D-4495-8976-848C7AAE2715 Q39237421-BE1C8BC2-D1AC-4EDE-B683-A731E0F8446F Q39243052-5B1C182B-DCDB-408B-BD68-0C39DFF012BF Q39432317-49EF0E3D-F822-459A-AD4B-424E354E7025 Q39450241-763885CF-64F2-47E2-A082-876D8E3E948C Q41252003-C1E69DA2-1D64-4D67-9E39-F6BDD16B550F Q42378297-F4424FAF-463B-45D6-AE48-69B3B634F7D6 Q45874243-2E8C4E63-0AC2-47EC-AE5A-381CE53DCF4F Q47112549-9B6CC227-892E-4CAC-9F50-5A2E413F6C14 Q47193084-2D9EFFCC-1842-404E-AA07-DA2A2504D07F Q47820469-AAB4CFF3-9796-4E36-ABE2-F2E652BA3C3D Q48640926-3E3B86A3-EF5C-4F1D-BAC3-8322CCE844D3 Q52689465-E357096B-0462-4E3A-8B47-162AA71DEBD9 Q53690286-13F21522-4261-4A89-8948-D8763A67A73D

P2860

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

http://www.wikidata.org/entity/Q35071430

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

@ast

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

@en

type

label

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

@ast

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

@en

prefLabel

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

@ast

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

@en

P1433

Q35071430-A03960ED-CD99-4837-A86F-6B1E48F03026

P1476

Q35071430-9EF7968C-D8FE-4FD1-89D0-EA6CCC385DEE

P2093

Q35071430-0C3DEAA4-9375-4235-A8EE-B821525B3A13

Q35071430-2A7C08FB-C42B-4CDD-95B2-4E6F526BAF0D

Q35071430-3082113D-6878-46C7-A69B-5ECB36523EB2

Q35071430-3AD9C853-A1BC-4931-A0CD-7EFFA0104143

Q35071430-7270E766-B10E-4626-AC09-9254F966768C

Q35071430-88EC7792-E3C6-4797-AC39-DB4C3781EE79

Q35071430-FA05E93F-61D1-4E7B-AB93-B33CC0A1281E

P2860

Q35071430-09FE88AC-8078-4D1D-BEEB-9E1578070717

Q35071430-0DD0C4CA-CEBA-4BDE-A9E8-E2F1D5A03D1D

Q35071430-1695A123-9B2F-4E00-80B1-DDCB6FCC29EB

Q35071430-16ABECB4-A2B6-457D-9CC1-667CA22DA8BA

Q35071430-181F791A-C40E-4660-8C30-21C2A7E4FC00

Q35071430-1B45D32D-1781-45AF-9F4B-160EA21EF495

Q35071430-1F3443A6-BD43-48FA-8C32-8E9FD545405B

Q35071430-23226F5E-631B-4048-824D-12D6CD92E621

Q35071430-23DD3EC9-2149-4767-8BDE-2937D46723E7

Q35071430-275B92BD-47BB-4DE2-B781-65AE7220A6DA

P304

Q35071430-1D8104CA-0CD1-455B-B23B-BBAAD35E63B3

P31

Q35071430-50C83834-46C5-4F85-827B-906D28518C72

P356

Q35071430-07142235-1C78-4927-B330-D6046F94FA2D

P433

Q35071430-3C1ECABF-BD04-4CA1-9B1A-DAF0CAB0B6A9

P478

Q35071430-3545EBB1-7E9D-495B-9968-DB02A8E09939

P50

Q35071430-9112A0DC-9D63-4774-8AF4-328D814DADF6

Q35071430-B4BA3FA9-9F78-4B02-A7F5-8F39D4241B93

P577

Q35071430-E20B0A66-4D88-4890-99E6-382921475F3C

P698

Q35071430-FA3A633E-CD23-4E92-9FE6-CEFE5B4B48AA

P932

Q35071430-9FB2CDAD-7F86-42F0-8D5A-7D22FAE59EE6

P356

2326-6066.CIR-14-0163

P1433

Cancer immunology research

P1476

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

@en

P2093

Ashwini Balakrishnan

http://www.w3.org/2001/XMLSchema#string

Carolina Berger

http://www.w3.org/2001/XMLSchema#string

Daniel Sommermeyer

http://www.w3.org/2001/XMLSchema#string

Michael Berger

http://www.w3.org/2001/XMLSchema#string

Paula L Kosasih

http://www.w3.org/2001/XMLSchema#string

Paulina J Paszkiewicz

http://www.w3.org/2001/XMLSchema#string

Stanley R Riddell

http://www.w3.org/2001/XMLSchema#string

P2860

NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma

A novel family of cell surface receptors with tyrosine kinase-like domain

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

ROR1, an embryonic protein with an emerging role in cancer biology

A new mathematical model for relative quantification in real-time RT-PCR

Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies

Inducible apoptosis as a safety switch for adoptive cell therapy

Adipokines in inflammation and metabolic disease

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

P304

206-216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-14-0163

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Michael Hudecek

Christoph Rader

P577

2014-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25355068

http://www.w3.org/2001/XMLSchema#string

P932

4324006

http://www.w3.org/2001/XMLSchema#string